Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 631,300 shares, an increase of 437.3% from the January 15th total of 117,500 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 3,650,000 shares, the short-interest ratio is currently 0.2 days.

Virpax Pharmaceuticals Stock Performance

NASDAQ VRPX traded down $0.01 during trading on Wednesday, reaching $0.26. The company’s stock had a trading volume of 125,537 shares, compared to its average volume of 436,467. Virpax Pharmaceuticals has a 12 month low of $0.23 and a 12 month high of $5.48. The firm has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.60.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. Institutional investors own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.